ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alirocumab

Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.

Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 24, 201548 company-led studies, 1 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only300 open or runningphase 4since Dec 24, 2015Feb 1, 2011none ahead
Regeneron Pharmaceuticals161 open or runningphase 4since Oct 28, 2016Nov 20, 2009Dec 29, 2026phase 2 · NCT07477704
Kobe Universityits history only20 open or runningphase 4since May 7, 2018May 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2009First study: phase 1 study in HealthyFirst studyNCT01026597 · 40 enrolled · United States
  2. Feb 22, 2010Phase 1 study in Healthy VolunteersNCT01074372 · 32 enrolled · United States
  3. Jul 9, 2010Phase 1 study in HypercholesterolemiaNCT01161082 · 72 enrolled · United States
  4. Dec 23, 2010Phase 2 study in HypercholesterolemiaNCT01266876 · 77 enrolled · United States, Canada
  5. Mar 27, 2012Phase 2 study in HypercholesterolemiaNCT01576484 · 58 enrolled · United States, Canada
  6. May 22, 2012Phase 2 study in HypercholesterolemiaNCT01604824 · 23 enrolled · United States, France
  7. Oct 8, 20122 phase 3 studiesNCT01709513, NCT01709500
  8. Nov 9, 20122 phase 3 studies in HypercholesterolemiaNCT01730053, NCT01730040
  9. Aug 19, 2013Phase 3 study in HypercholesterolemiaNCT01926782 · 803 enrolled · United States, Bulgaria, Canada and more
  10. Dec 22, 2014Phase 3 study in Heterozygous Familial HypercholesterolemiaNCT02326220 · 62 enrolled · United States, Germany
  11. Oct 28, 2016Phase 4 study in HypercholesterolemiaNCT02957682 · 2,176 enrolled · United States, Bulgaria, Chile and more
  12. May 15, 2017Phase 3 study in Homozygous Familial HypercholesterolemiaNCT03156621 · 69 enrolled · United States, Austria, Canada and more
  13. Sep 6, 2018Phase 4 study in Heterozygous Familial HypercholesterolemiaNCT03694197 · 1,389 enrolled · United States, Bulgaria, Estonia and more
  14. Mar 12, 2026Phase 2 study in HypercholesterolemiaNCT07477704 · 438 enrolled · United States

Ahead

  1. Dec 29, 2026Primary completion: phase 2 study in HypercholesterolemiaNCT07477704

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 16 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07477704Hypercholesterolemia · United States2Active, not recruitingDec 29, 2026438
NCT03694197Heterozygous Familial Hypercholesterolemia · United States, Bulgaria, Estonia and more4TerminatedApr 8, 20201,389
NCT03156621Homozygous Familial Hypercholesterolemia · United States, Austria, Canada and more3CompletedSep 27, 201969
NCT02957682Hypercholesterolemia · United States, Bulgaria, Chile and more4CompletedMar 5, 20202,176
NCT02326220Heterozygous Familial Hypercholesterolemia · United States, Germany3CompletedJan 31, 201662
NCT01926782Hypercholesterolemia · United States, Bulgaria, Canada and more3CompletedSep 2014803
NCT01730053Hypercholesterolemia · United States, Australia, Canada and more3CompletedApr 30, 2014305
NCT01730040Hypercholesterolemia · United States, Australia, Canada and more3CompletedApr 2014355
NCT01709513Hypercholesterolemia · United States, Austria, Canada and more3CompletedMay 31, 2014314
NCT01709500Heterozygous Familial Hypercholesterolemia · Czech Republic, Netherlands, Norway and more3CompletedMay 2014249
NCT01604824Hypercholesterolemia · United States, France2CompletedJun 2, 201423
NCT01576484Hypercholesterolemia · United States, Canada2CompletedDec 22, 201658
NCT01266876Hypercholesterolemia · United States, Canada2CompletedNov 201177
NCT01161082Hypercholesterolemia · United States1CompletedMay 201172
NCT01074372Healthy Volunteers · United States1CompletedNov 201032
NCT01026597Healthy · United States1CompletedOct 201040

How it is read

Names in the registry

  • “Alirocumab”, 28 entries
  • “alirocumab SAR236553 (REGN727)”, 8 entries
  • “Alirocumab SAR236553 (REGN727)”, 2 entries
  • “alirocumab”, 2 entries
  • “REGN727”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.